Guggenheim Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.5M Buy
35,351
+1,263
+4% +$1.28M 0.25% 83
2025
Q4
$36.6M Buy
34,088
+900
+3% +$861K 0.26% 75
2025
Q3
$25.3M Buy
33,188
+7,757
+31% +$5.77M 0.18% 108
2025
Q2
$19.8M Buy
25,431
+1,411
+6% +$1.1M 0.16% 120
2025
Q1
$19.8M Sell
24,020
-8,346
-26% -$6.94M 0.18% 108
2024
Q4
$25M Sell
32,366
-4,349
-12% -$3.6M 0.2% 99
2024
Q3
$32.5M Sell
36,715
-9,833
-21% -$8.84M 0.23% 81
2024
Q2
$42.1M Sell
46,548
-4,491
-9% -$3.59M 0.3% 61
2024
Q1
$39.7M Sell
51,039
-15,217
-23% -$10.8M 0.28% 68
2023
Q4
$38.6M Sell
66,256
-10,777
-14% -$6.29M 0.29% 63
2023
Q3
$41.4M Sell
77,033
-20,163
-21% -$10.4M 0.36% 49
2023
Q2
$45.6M Buy
97,196
+3,915
+4% +$1.64M 0.36% 45
2023
Q1
$32M Sell
93,281
-297
-0.3% -$100K 0.27% 70
2022
Q4
$34.2M Sell
93,578
-25,312
-21% -$8.97M 0.3% 68
2022
Q3
$38.4M Sell
118,890
-8,714
-7% -$2.76M 0.35% 48
2022
Q2
$41.4M Sell
127,604
-25,960
-17% -$7.79M 0.33% 52
2022
Q1
$44M Sell
153,564
-8,293
-5% -$2.13M 0.26% 63
2021
Q4
$44.7M Buy
161,857
+8,252
+5% +$2.09M 0.23% 78
2021
Q3
$35.5M Buy
153,605
+33,882
+28% +$8.36M 0.21% 81
2021
Q2
$27.5M Sell
119,723
-3,606
-3% -$724K 0.16% 118
2021
Q1
$23M Sell
123,329
-4,046
-3% -$791K 0.15% 139
2020
Q4
$21.5M Buy
127,375
+23,814
+23% +$3.56M 0.13% 125
2020
Q3
$15.3M Sell
103,561
-22,353
-18% -$3.46M 0.11% 168
2020
Q2
$20.7M Buy
125,914
+22,597
+22% +$3.47M 0.16% 116
2020
Q1
$14.3M Sell
103,317
-82,154
-44% -$11.3M 0.14% 139
2019
Q4
$24.4M Buy
185,471
+35,150
+23% +$4.07M 0.18% 113
2019
Q3
$16.8M Buy
150,321
+21,965
+17% +$2.45M 0.13% 172
2019
Q2
$14.2M Sell
128,356
-9,198
-7% -$1.08M 0.12% 191
2019
Q1
$17.9M Sell
137,554
-13,195
-9% -$1.6M 0.15% 134
2018
Q4
$17.4M Sell
150,749
-22,489
-13% -$2.51M 0.15% 131
2018
Q3
$18.6M Buy
173,238
+18,953
+12% +$1.89M 0.12% 160
2018
Q2
$13.2M Sell
154,285
-535,834
-78% -$44M 0.09% 248
2018
Q1
$53.4M Sell
690,119
-11,780
-2% -$948K 0.13% 259
2017
Q4
$59.3M Buy
701,899
+124,217
+22% +$10.6M 0.14% 230
2017
Q3
$49.4M Sell
577,682
-52,067
-8% -$4.27M 0.12% 309
2017
Q2
$51.8M Buy
629,749
+73,997
+13% +$6.04M 0.14% 261
2017
Q1
$46.7M Sell
555,752
-60,179
-10% -$4.82M 0.13% 320
2016
Q4
$45.3M Buy
615,931
+106,431
+21% +$7.93M 0.13% 281
2016
Q3
$40.9M Sell
509,500
-109,821
-18% -$8.79M 0.13% 271
2016
Q2
$48.8M Buy
619,321
+52,264
+9% +$3.93M 0.15% 177
2016
Q1
$40.8M Sell
567,057
-4,713
-0.8% -$357K 0.13% 243
2015
Q4
$48.2M Sell
571,770
-49,058
-8% -$4.07M 0.14% 198
2015
Q3
$52M Sell
620,828
-268,495
-30% -$22.7M 0.16% 132
2015
Q2
$74.2M Sell
889,323
-177,332
-17% -$13.5M 0.18% 86
2015
Q1
$77.5M Buy
1,066,655
+122,843
+13% +$8.75M 0.18% 92
2014
Q4
$65.1M Sell
943,812
-97,894
-9% -$6.61M 0.16% 129
2014
Q3
$67.6M Sell
1,041,706
-20,462
-2% -$1.3M 0.16% 105
2014
Q2
$66M Sell
1,062,168
-155,190
-13% -$9.26M 0.17% 109
2014
Q1
$71.7M Buy
1,217,358
+161,122
+15% +$8.99M 0.2% 69
2013
Q4
$53.9M Buy
1,056,236
+1,832
+0.2% +$91.7K 0.16% 113
2013
Q3
$53.1M Buy
1,054,404
+239,250
+29% +$12.5M 0.19% 73
2013
Q2
$40M Buy
+815,154
New +$44.4M 0.17% 91

Other funds holding LLY

Guggenheim Capital's LLY Position: Q1 2026 in Review

Guggenheim Capital increased its Eli Lilly (LLY) stake by 3.7% in Q1 2026, buying an estimated $1.28M and bringing the position to 35,351 shares worth $32.5M. The position accounts for 0.25% of the portfolio, ranked #83.

Guggenheim Capital first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $77.5M in Q1 2015. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Guggenheim Capital held 35,351 shares of Eli Lilly worth $32.5M as of Q1 2026.
  • Guggenheim Capital bought 1,263 Eli Lilly shares in Q1 2026, an estimated $1.28M.
  • Eli Lilly made up 0.25% of Guggenheim Capital's portfolio in Q1 2026, its #83 holding.
  • Guggenheim Capital first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's Eli Lilly position peaked at $77.5M in Q1 2015.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.